June 1, 2020 / 6:31 AM / a month ago

AstraZeneca's heart drug gets FDA nod

FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

(Reuters) - AstraZeneca Plc said on Monday the U.S. Food and Drug Administration has approved its drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.

The FDA approval was based on positive results from a late-stage trial of the drug, Brilinta, along with aspirin, which showed a statistically significant reduction in major adverse cardiovascular events, when compared to aspirin alone.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Vinay Dwivedi

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below